

Olivier Thaunat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4142847/publications.pdf>

Version: 2024-02-01

93
papers

4,188
citations

101543

36
h-index

133252

59
g-index

121
all docs

121
docs citations

121
times ranked

4759
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphoid neogenesis in chronic rejection: Evidence for a local humoral alloimmune response. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14723-14728.	7.1	227
2	Detection of C3d-Binding Donor-Specific Anti-HLA Antibodies at Diagnosis of Humoral Rejection Predicts Renal Graft Loss. Journal of the American Society of Nephrology: JASN, 2015, 26, 457-467.	6.1	226
3	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney International, 2020, 98, 1549-1558.	5.2	213
4	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, 14923.	2.3	191
5	Is COVID-19 infection more severe in kidney transplant recipients?. American Journal of Transplantation, 2021, 21, 1295-1303.	4.7	190
6	B Cell Survival in Intragraft Tertiary Lymphoid Organs After Rituximab Therapy. Transplantation, 2008, 85, 1648-1653.	1.0	125
7	Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. Journal of the American Society of Nephrology: JASN, 2016, 27, 615-625.	6.1	116
8	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. Kidney International, 2019, 95, 188-198.	5.2	116
9	Polyclonal expansion of TCR V β 21.3 CD4 and CD8 T cells is a hallmark of multisystem inflammatory syndrome in children. Science Immunology, 2021, 6, .	11.9	105
10	Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney International, 2021, 100, 477-479.	5.2	101
11	Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nature Communications, 2019, 10, 5350.	12.8	100
12	COVID-19 vaccination in kidney transplant recipients. Nature Reviews Nephrology, 2021, 17, 785-787.	9.6	99
13	Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. Annals of Internal Medicine, 2022, 175, 455-456.	3.9	98
14	Clinicopathological Findings of Chronic Rejection in a Face Grafted Patient. Transplantation, 2015, 99, 2644-2650.	1.0	96
15	IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). Kidney International, 2020, 98, 1568-1577.	5.2	85
16	Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens. Journal of the American Society of Nephrology: JASN, 2019, 30, 692-709.	6.1	81
17	Chronic Rejection in Human Vascularized Composite Allotransplantation (Hand and Face Recipients). Transplantation, 2016, 100, 2053-2061.	1.0	73
18	A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney International, 2022, 101, 390-402.	5.2	72

#	ARTICLE	IF	CITATIONS
19	Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs. <i>Frontiers in Immunology</i> , 2016, 7, 646.	4.8	69
20	Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. <i>Toxins</i> , 2020, 12, 300.	3.4	66
21	High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors. <i>ELife</i> , 2017, 6, .	6.0	65
22	Allorecognition and the spectrum of kidney transplant rejection. <i>Kidney International</i> , 2022, 101, 692-710.	5.2	65
23	The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. <i>Kidney International</i> , 2021, 100, 928-936.	5.2	61
24	Amâ€œBâ€œvalent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. <i>Blood</i> , 2010, 116, 515-521.	1.4	60
25	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2168-2183.	6.1	60
26	Missing Self-Induced Activation of NK Cells Combines with Non-Complement-Fixing Donor-Specific Antibodies to Accelerate Kidney Transplant Loss in Chronic Antibody-Mediated Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 479-494.	6.1	56
27	Humoral immunity in chronic allograft rejection: Puzzle pieces come together. <i>Transplant Immunology</i> , 2012, 26, 101-106.	1.2	55
28	Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: Insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. <i>Transplant Immunology</i> , 2009, 20, 209-211.	1.2	52
29	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. <i>Science Translational Medicine</i> , 2022, 14, eabl6141.	12.4	52
30	Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2675-2681.	4.7	48
31	A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. <i>Kidney International</i> , 2012, 81, 207-219.	5.2	47
32	Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1890-1900.	6.1	47
33	CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 275.	4.8	47
34	SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. <i>American Journal of Transplantation</i> , 2021, 21, 2749-2761.	4.7	46
35	Recent advances in renal transplantation: antibody-mediated rejection takes center stage. <i>F1000prime Reports</i> , 2015, 7, 51.	5.9	44
36	Missing Selfâ€œInduced Microvascular Rejection of Kidney Allografts: A Population-Based Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2070-2082.	6.1	38

#	ARTICLE	IF	CITATIONS
37	Atheroprotective Effect of CD31 Receptor Globulin Through Enrichment of Circulating Regulatory T-Cells. <i>Journal of the American College of Cardiology</i> , 2007, 50, 344-350.	2.8	37
38	Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection. <i>Journal of Clinical Investigation</i> , 2017, 128, 219-232.	8.2	37
39	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. <i>Kidney International</i> , 2014, 85, 182-190.	5.2	35
40	Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Soci�t� francophone du diab�te (SFD), Soci�t� fran�aise d'endocrinologie (SFE), Soci�t� francophone de transplantation (SFT) and Soci�t� fran�aise de nephrologie "��dialyse��" transplantation (SFNDT). <i>Diabetes and Metabolism</i> , 2019, 45, 224-237.	2.9	35
41	Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2413-2423.	4.7	34
42	Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. <i>Kidney International</i> , 2022, 102, 442-444.	5.2	34
43	Lymphoid neogenesis in chronic rejection. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 16-19.	1.6	33
44	Direct and Indirect Effects of Alloantibodies Link Neointimal and Medial Remodeling in Graft Arteriosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2359-2365.	2.4	32
45	mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?. <i>Transplant International</i> , 2017, 30, 647-657.	1.6	32
46	Capillary Thrombosis in the Skin. <i>Transplantation</i> , 2016, 100, 954-957.	1.0	30
47	The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1853-1863.	0.7	30
48	Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection. <i>Kidney International</i> , 2017, 92, 214-226.	5.2	28
49	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1084-1096.	6.1	28
50	Immunopathology of rejection. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 596-601.	1.6	26
51	Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.	0.8	25
52	Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group. <i>Transplant International</i> , 2021, 34, 1005-1018.	1.6	23
53	Diagnostic performance of kSORT, a blood-based mRNA assay for noninvasive detection of rejection after kidney transplantation: A retrospective multicenter cohort study. <i>American Journal of Transplantation</i> , 2021, 21, 740-750.	4.7	22
54	Pregnancy outcomes in simultaneous pancreas and kidney transplant recipients: a national French survey study. <i>Transplant International</i> , 2017, 30, 893-902.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Finding the safe place between the hammer and the anvil: sounding the depth of therapeutic immunosuppression. <i>Kidney International</i> , 2015, 88, 1226-1228.	5.2	16
56	Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 3178.	4.8	16
57	Alloimmune-induced intragraft lymphoid neogenesis promotes B-cell tolerance breakdown that accelerates chronic rejection. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 368-374.	1.6	15
58	Mechanisms underlying human genetic diversity: consequence for antigraft antibody responses. <i>Transplant International</i> , 2018, 31, 239-250.	1.6	15
59	Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine. <i>American Journal of Transplantation</i> , 2022, 22, 1442-1450.	4.7	15
60	Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings. <i>Frontiers in Immunology</i> , 2022, 13, 818569.	4.8	15
61	B Cells and Antibodies in Transplantation. <i>Transplantation</i> , 2016, 100, 1460-1464.	1.0	14
62	Allograft recognition by recipient's natural killer cells: Molecular mechanisms and role in transplant rejection. <i>Hla</i> , 2021, 98, 191-199.	0.6	14
63	Cell Therapy to Induce Allograft Tolerance: Time to Switch to Plan B?. <i>Frontiers in Immunology</i> , 2015, 6, 149.	4.8	12
64	B Cells Loaded with Synthetic Particulate Antigens: A Versatile Platform To Generate Antigen-Specific Helper T Cells for Cell Therapy. <i>Nano Letters</i> , 2016, 16, 297-308.	9.1	12
65	Infections after upper extremity allotransplantation: a worldwide population cohort study, 1998â€2017. <i>Transplant International</i> , 2019, 32, 693-701.	1.6	12
66	Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes. <i>Frontiers in Immunology</i> , 2019, 10, 513.	4.8	11
67	A comprehensive assessment of long-term SARS-CoV-2â€specific adaptive immune memory inâ€convalescent COVID-19 Solid Organ Transplant recipients. <i>Kidney International</i> , 2022, 101, 1027-1038.	5.2	10
68	Pretransplant endotrophin predicts delayed graft function after kidney transplantation. <i>Scientific Reports</i> , 2022, 12, 4079.	3.3	10
69	Alloimmune Risk Stratification for Kidney Transplant Rejection. <i>Transplant International</i> , 0, 35, .	1.6	10
70	Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays?. <i>Transplant Immunology</i> , 2016, 35, 23-28.	1.2	9
71	Hypothermic pulsatile preservation of kidneys from uncontrolled deceased donors after cardiac arrest - a retrospective study. <i>Transplant International</i> , 2017, 30, 1284-1291.	1.6	9
72	Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: â€Liaisons dangereusesâ€. <i>Transplant Immunology</i> , 2019, 54, 47-51.	1.2	9

#	ARTICLE	IF	CITATIONS
73	Innate (and Innate-like) Lymphoid Cells: Emerging Immune Subsets With Multiple Roles Along Transplant Life. <i>Transplantation</i> , 2021, 105, e322-e336.	1.0	9
74	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.8	8
75	Impact of Covid-19 on kidney transplant and waiting list patients: Lessons from the first wave of the pandemic. <i>Nephrologie Et Therapeutique</i> , 2021, 17, 245-251.	0.5	8
76	Soothing touch of CD31 protects endothelium during cellular immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13133-13134.	7.1	7
77	Immunological Challenges in Vascularised Composite Allotransplantation. <i>Current Transplantation Reports</i> , 2015, 2, 276-283.	2.0	6
78	Humoral Alloreactivity in VCA Recipients: Should We Learn From Our Experience?. <i>Transplantation</i> , 2020, 104, 2003-2010.	1.0	6
79	Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. <i>Kidney International Reports</i> , 2020, 5, 2202-2211.	0.8	6
80	An integrated view of immune monitoring in vascularized composite allotransplantation. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 516-522.	1.6	5
81	Immunological Monitoring in Beta Cell Replacement: Towards a Pathophysiology-Guided Implementation of Biomarkers. <i>Current Diabetes Reports</i> , 2021, 21, 19.	4.2	5
82	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. <i>American Journal of Transplantation</i> , 2022, 22, 1430-1441.	4.7	5
83	Allotransplantation of kidney from unrelated living donor with loin pain haematuria syndrome. <i>Transplant International</i> , 2014, 27, e24-e26.	1.6	4
84	Performances of creatinine-based glomerular filtration rate estimating equations in simultaneous pancreas-kidney transplant recipients: a single center cohort study. <i>Transplant International</i> , 2019, 32, 75-83.	1.6	4
85	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. <i>Journal of Immunology</i> , 2016, 196, 4075-4081.	0.8	3
86	Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2032.	2.4	3
87	Low T Cell Responsiveness in the Early Phase of COVID-19 Associates with Progression to Severe Pneumonia in Kidney Transplant Recipients. <i>Viruses</i> , 2022, 14, 542.	3.3	3
88	De Novo Complement-Binding Anti-HLA Antibodies in Heart Transplanted Patients Is Associated with Severe Cardiac Allograft Vasculopathy and Poor Long-Term Survival. <i>Journal of Clinical Medicine</i> , 2022, 11, 3731.	2.4	2
89	Microvascular inflammation: Gene expression changes do not necessarily reflect pathogenesis. <i>American Journal of Transplantation</i> , 2022, 22, 3180-3181.	4.7	2
90	The authors reply. <i>Kidney International</i> , 2021, 99, 771-772.	5.2	1

#	ARTICLE	IF	CITATIONS
91	Tâ€and Bâ€cell therapy in solid organ transplantation: current evidence and future expectations. Transplant International, 2021, 34, 1594-1606.	1.6	1
92	Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment. Nephrology Dialysis Transplantation, 2022, 37, 2555-2568.	0.7	1
93	FP697ACTIVABILITY OF CIRCLATING TFH17 PREDICTS HUMORAL RESPONSE TO THYMUS-DEPENDENT ANTIGENS. Nephrology Dialysis Transplantation, 2018, 33, i281-i281.	0.7	0